Researchers have found two different compounds that can block malaria transmission when added to pre-existing treatment regimes. Credit: turkletom

Emergent BioSolutions has reported positive findings from the interim analysis of a Phase II clinical trial being conducted to assess its chikungunya virus-like particle (CHIKV-VLP) vaccine candidate.

According to the data, around 98% of the trial subjects who received a single dose of the vaccine generated a neutralising antibody response against the virus by day seven.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The response was observed to be sustained through the six-month visit.

Spread via mosquitoes, chikungunya virus is characterised by fever, joint pain, headache, muscle pain, joint swelling or rash. The infection does not currently have a preventive or treatment therapy.

“The Phase II trial assessed the safety and immunogenicity of the CHIKV-VLP vaccine candidate in multiple dosing regimens.”

Emergent BioSolutions licensed the CHIKV-VLP chikungunya virus vaccine candidate from the US National Institutes of Health’s National Institute of Allergy and Infectious Diseases.

Virus-like particle (VLP) vaccines are multi-protein products with organisation and conformation similar to that of natural viruses. However, VLP vaccines lack the viral genome and are intended to stimulate a strong immune response and improve antibody generation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Prior research demonstrated that VLP vaccines are highly immunogenic, safe and usually induce high titer neutralising antibodies to protect against the virus.

The parallel-group, randomised, double-blind, dose-finding Phase II trial assessed the safety and immunogenicity of the CHIKV-VLP vaccine candidate in multiple dosing regimens.

It was performed in a total of 415 healthy adults at three sites in the US. Subjects received a one or two-dose series of the investigational vaccine with or without an adjuvant over four weeks.

Following one dose, 74%-98% of the participants had seroconversion within seven days. All subjects experienced seroconversion by 28 days after the last dose.

The vaccine candidate was found to be well-tolerated without any significant vaccine-related safety concerns.